<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087253</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00127427</org_study_id>
    <nct_id>NCT03087253</nct_id>
  </id_info>
  <brief_title>The LD Lync Study - Natural History Study of Genetic Lipodystrophy Syndromes</brief_title>
  <official_title>Prospective Multicenter Natural History Study of Genetic Lipodystrophy Syndromes to Determine Prevalence, Incidence and Predictors of Diabetes and Severe Hypertriglyceridemia, and Their Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Genetic lipodystrophy syndromes are extremely rare, orphan diseases with overall estimated
      prevalence of less than 2,000 in the United States. These rare disorders characterized by
      selective loss of adipose tissue and predisposition to insulin resistance and its metabolic
      complications diabetes, dyslipidemia and hepatic steatosis. Due to these metabolic problems,
      atherosclerotic vascular disease, recurrent episodes of acute pancreatitis, cirrhosis and
      other morbidities complicate the lives of these patients.

      In the last few years, several genes for CGL (AGPAT2, BSCL2, CAV1 and PTRF); FPL (LMNA,
      PPARG, AKT2, CIDEC, LIPE, PLIN1, PCYT1A and ADRA2A); MAD (LMNA and ZMPSTE24); APS (LMNA);
      autoinflammatory (PSMB8); NPS (FBN1, CAV1); SHORT syndrome (PIK3R1); and MDP syndrome (POLD1)
      have been identified. However, there is paucity of information about the natural history of
      these rare syndromes, especially genotype-specific causes of morbidity and mortality.

      To overcome the problems outlined above, this multicenter, collaborative, prospective,
      observational natural history cohort study will be conducted on approximately 500 patients
      with genetic lipodystrophy syndromes. Patients will be assessed on a yearly basis for
      approximately 4 years to collect robust clinical, metabolic, morbidity and mortality data.
      Medical history and patient questionnaires will be completed on a yearly basis by patients
      registered in the study. Clinical data such as vitals, laboratory results and anthropometric
      measurements will also be collected from patients' medical records if available.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>Prevalence of diabetes mellitus</measure>
    <time_frame>4 years</time_frame>
    <description>Number of subjects with diabetes mellitus or who develop diabetes mellitus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of severe hypertriglyceridemia</measure>
    <time_frame>4 years</time_frame>
    <description>Number of subjects with severe hypertriglyceridemia (greater than 500 md/dL) or who develop severe hypertriglyceridemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe morbidities and causes of mortality</measure>
    <time_frame>4 years</time_frame>
    <description>Incidence of severe morbidities (acute pancreatitis, congestive heart failure, cirrhosis, liver failure) and causes of mortality in subjects</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Genetic Lipodystrophy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a clinical diagnosis of genetic lipodystrophy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of genetic lipodystrophy Supportive data: 1) Presence of biallelic
             known disease-causing variants in the genes for autosomal recessive lipodystrophy
             syndromes; 2) Presence of a known (or de novo loss of function) disease-causing
             variant in the genes for autosomal dominant lipodystrophy syndromes.

        Exclusion Criteria:

          -  HIV-infected patients with lipodystrophy

          -  Drug-induced lipodystrophy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elif A Oral, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam Neidert, M.S.</last_name>
    <phone>734-615-0539</phone>
    <email>aneidert@med.umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elif Oral, M.D.</last_name>
    <phone>734-615-7271</phone>
    <email>eliforal@med.umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam H Neidert, MS</last_name>
      <phone>734-615-0539</phone>
      <email>aneidert@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elif A Oral, MD</last_name>
      <phone>734-615-7271</phone>
      <email>eliforal@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Elif A Oral, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nevin N Ajluni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corey Lager, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Elif Oral</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

